The potential role of appetite in predicting weight changes during treatment with olanzapine.
BACKGROUND
Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite.


METHODS
Data were used from adult patients for whom both appetite and weight data were available from 4 prospective, 12- to 24-week clinical trials. Patients' appetites were assessed with Eating Behavior Assessment (EBA, Study 1), Platypus Appetite Rating Scale (PARS, Study 2), Eating Inventory (EI, Study 3), Food Craving Inventory (FCI, Study 3), and Eating Attitude Scale (EAS, Study 4).


RESULTS
In Studies 1 (EBA) and 4 (EAS), patients who reported overall score increases on appetite scales, indicating an increase in appetite, experienced the greatest overall weight gains. However, in Studies 2 (PARS) and 3 (EI, FCI), patients who reported overall score increases on appetite scales did not experience greater weight changes than patients not reporting score increases. Early weight changes (2-4 weeks) were more positively correlated with overall weight changes than early or overall score changes on any utilized appetite assessment scale. No additional information was gained by adding early appetite change to early weight change in correlation to overall weight change.


CONCLUSIONS
Early weight changes may be a more useful predictor for long-term weight changes than early score changes on appetite assessment scales.


BACKGROUND
This report represents secondary analyses of 4 clinical studies. Studies 1, 2, and 3 were registered at http://clinicaltrials.gov/ct2/home, under NCT00190749, NCT00303602, and NCT00401973, respectively. Study 4 predates the registration requirements for observational studies that are not classified as category 1 observational studies.
Case
Michael
M
Lilly USA, LLC, Indianapolis, IN, USA. case_michael@lilly.com
Treuer
Tamas
T
Karagianis
Jamie
J
Hoffmann
Vicki Poole
VP
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects* / Q000502:physiology; D001069:Appetite Regulation / Q000187:drug effects; D001569:Benzodiazepines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D017327:Clinical Trials, Phase IV as Topic / Q000706:statistics & numerical data; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011336:Probability; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine